536 related articles for article (PubMed ID: 17178267)
1. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment.
Crettol S; Déglon JJ; Besson J; Croquette-Krokar M; Hämmig R; Gothuey I; Monnat M; Eap CB
Clin Pharmacol Ther; 2006 Dec; 80(6):668-81. PubMed ID: 17178267
[TBL] [Abstract][Full Text] [Related]
2. Increased (R)-methadone plasma concentrations by quetiapine in cytochrome P450s and ABCB1 genotyped patients.
Uehlinger C; Crettol S; Chassot P; Brocard M; Koeb L; Brawand-Amey M; Eap CB
J Clin Psychopharmacol; 2007 Jun; 27(3):273-8. PubMed ID: 17502774
[TBL] [Abstract][Full Text] [Related]
3. A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels.
Leon Jd; Susce MT; Pan RM; Wedlund PJ; Orrego ML; Diaz FJ
Pharmacopsychiatry; 2007 May; 40(3):93-102. PubMed ID: 17541883
[TBL] [Abstract][Full Text] [Related]
4. Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment.
Crettol S; Déglon JJ; Besson J; Croquette-Krokkar M; Gothuey I; Hämmig R; Monnat M; Hüttemann H; Baumann P; Eap CB
Clin Pharmacol Ther; 2005 Dec; 78(6):593-604. PubMed ID: 16338275
[TBL] [Abstract][Full Text] [Related]
5. ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine.
Jaquenoud Sirot E; Knezevic B; Morena GP; Harenberg S; Oneda B; Crettol S; Ansermot N; Baumann P; Eap CB
J Clin Psychopharmacol; 2009 Aug; 29(4):319-26. PubMed ID: 19593168
[TBL] [Abstract][Full Text] [Related]
6. Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients.
Wei-lin W; Jing J; Shu-sen Z; Li-hua W; Ting-bo L; Song-feng Y; Sheng Y
Liver Transpl; 2006 May; 12(5):775-80. PubMed ID: 16628701
[TBL] [Abstract][Full Text] [Related]
7. ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals.
Coller JK; Barratt DT; Dahlen K; Loennechen MH; Somogyi AA
Clin Pharmacol Ther; 2006 Dec; 80(6):682-90. PubMed ID: 17178268
[TBL] [Abstract][Full Text] [Related]
8. CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response.
Gex-Fabry M; Eap CB; Oneda B; Gervasoni N; Aubry JM; Bondolfi G; Bertschy G
Ther Drug Monit; 2008 Aug; 30(4):474-82. PubMed ID: 18641553
[TBL] [Abstract][Full Text] [Related]
9. Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action.
Lötsch J; Skarke C; Wieting J; Oertel BG; Schmidt H; Brockmöller J; Geisslinger G
Clin Pharmacol Ther; 2006 Jan; 79(1):72-89. PubMed ID: 16413243
[TBL] [Abstract][Full Text] [Related]
10. Effect of ABCB1 (MDR1) haplotypes derived from G2677T/C3435T on the pharmacokinetics of amlodipine in healthy subjects.
Kim KA; Park PW; Park JY
Br J Clin Pharmacol; 2007 Jan; 63(1):53-8. PubMed ID: 16869811
[TBL] [Abstract][Full Text] [Related]
11. Association of CYP2D6 ultrarapid metabolizer genotype with deficient patient satisfaction regarding methadone maintenance treatment.
Pérez de los Cobos J; Siñol N; Trujols J; del Río E; Bañuls E; Luquero E; Menoyo A; Queraltó JM; Baiget M; Alvarez E
Drug Alcohol Depend; 2007 Jul; 89(2-3):190-4. PubMed ID: 17234366
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and pharmacodynamics of methadone enantiomers after a single oral dose of racemate.
Boulton DW; Arnaud P; DeVane CL
Clin Pharmacol Ther; 2001 Jul; 70(1):48-57. PubMed ID: 11452244
[TBL] [Abstract][Full Text] [Related]
13. The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test.
Oneda B; Crettol S; Jaquenoud Sirot E; Bochud M; Ansermot N; Eap CB
Pharmacogenet Genomics; 2009 Nov; 19(11):877-83. PubMed ID: 19801957
[TBL] [Abstract][Full Text] [Related]
14. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation.
Zhang X; Liu ZH; Zheng JM; Chen ZH; Tang Z; Chen JS; Li LS
Clin Transplant; 2005 Oct; 19(5):638-43. PubMed ID: 16146556
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetics of acenocoumarol: CYP2C9, CYP2C19, CYP1A2, CYP3A4, CYP3A5 and ABCB1 gene polymorphisms and dose requirements.
Saraeva RB; Paskaleva ID; Doncheva E; Eap CB; Ganev VS
J Clin Pharm Ther; 2007 Dec; 32(6):641-9. PubMed ID: 18021343
[TBL] [Abstract][Full Text] [Related]
16. Impact of ABCB1 (MDR1) haplotypes on tacrolimus dosing in adult lung transplant patients who are CYP3A5 *3/*3 non-expressors.
Wang J; Zeevi A; McCurry K; Schuetz E; Zheng H; Iacono A; McDade K; Zaldonis D; Webber S; Watanabe RM; Burckart GJ
Transpl Immunol; 2006 Jan; 15(3):235-40. PubMed ID: 16431292
[TBL] [Abstract][Full Text] [Related]
17. Cytochrome P450 2D6 genotype and methadone steady-state concentrations.
Eap CB; Broly F; Mino A; Hämmig R; Déglon JJ; Uehlinger C; Meili D; Chevalley AF; Bertschy G; Zullino D; Kosel M; Preisig M; Baumann P
J Clin Psychopharmacol; 2001 Apr; 21(2):229-34. PubMed ID: 11270921
[TBL] [Abstract][Full Text] [Related]
18. Association between cyclosporine concentration and genetic polymorphisms of CYP3A5 and MDR1 during the early stage after renal transplantation.
Azarpira N; Aghdaie MH; Behzad-Behbahanie A; Geramizadeh B; Behzadi S; Malekhoseinie SA; Raisjalal GH; Rahsaz M; Pourgholami A; Sagheb F
Exp Clin Transplant; 2006 Jun; 4(1):416-9. PubMed ID: 16827636
[TBL] [Abstract][Full Text] [Related]
19. Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis.
Takada K; Arefayene M; Desta Z; Yarboro CH; Boumpas DT; Balow JE; Flockhart DA; Illei GG
Arthritis Rheum; 2004 Jul; 50(7):2202-10. PubMed ID: 15248218
[TBL] [Abstract][Full Text] [Related]
20. Effect of cytochrome P450 3A5*3 genotype on the stereoselective pharmacokinetics of amlodipine in healthy subjects.
Kim KA; Park PW; Park JY
Chirality; 2009 May; 21(5):485-91. PubMed ID: 18752284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
